Canadian Researchers Obtain A Simple Cure For Cancer, But Major Pharmaceutical Corporations Aren’t Interested

Source

EDMONTON, CANADA, May 14, 2011 /NewsRelease/ - Canadian scientists tested dichloroacetate (DCA) on human’s cells; it killed lung, breast and brain cancer cells and left the healthy cells alone. It was tested on Rats inflicted with severe tumors; their cells shrank once they were fed with water supplemented with DCA. The drug is widely available and is easy to use, so why the major drug companies aren’t involved? Or the Media thinking about this find?

Pharmaceutical companies are not investing in this cancer research because DCA method cannot be patented

Researchers at the University of Alberta, in Edmonton, Canada have cured cancer, yet there is a little ripple in the news or in TV. It’s a simple technique using very basic drug. The method employs dichloroacetate, which is currently used to treat metabolic disorders. So, there isn’t any concern of side effects or about their long-term effects.

This drug doesn’t require a patent, so anyone can employ it widely and cheaply compared to the costly cancer drugs made by major pharmaceutical companies.

In human bodies there is a natural cancer fighting Mitochindria, the powerhouse/engine of the human cell, however they need to be triggered to work. Scientists used to think these mitochondria cells were damaged and thus ineffective against cancer. So they used to focus on glycolysis, that is less effective in curing cancer and more wasteful. The drug manufacturers focused on this glycolysis method to fight cancer. This DCA however doesn’t rely on glycolysis instead on mitochondria; it triggers the mitochondria which in turn fights the cancer cells.

The side effect of this could it be also reactivates a process called apoptosis. You see, mitochondria contain an all-too-important self-destruct button that can not be pressed in cancer cells. Without it, tumors grow larger as cells refuse to be extinguished. Fully functioning mitochondria, thanks to DCA, can once again die.

With glycolysis switched off, the body produces less lactic acid, so the bad tissue around cancer cells doesn’t break down and seed new tumors.

Pharmaceutical companies are not investing in this research because DCA method cannot be patented, without a patent they can’t make money, like they are doing with their AIDS Patent. Because the pharmaceutical companies won’t develop this, the article says other independent laboratories should start producing this drug and do more research to confirm all the above findings and produce drugs. All the groundwork can be achieved in collaboration with the Universities, who will be glad to assist in such research and may develop an effective drug for curing cancer.

You can access the original research for this cancer here.

The updated clinical trials can be found here - http://www.medicorcancer.com/dca-data.html

The latest DCA research information -http://www.dca.med.ualberta.ca/Home/Updates/2010-05-12_Update.cfm

The University of Alberta results are encouraging and support the need for larger clinical trials with DCA. The research team hopes to secure additional funding to continue the ongoing trials with DCA at the University of Alberta.

From wiki

Dichloroacetic acid, often abbreviated DCA, is the chemical compound with formula CHCl2COOH. It is an acid, an analogue of acetic acid in which two of the three hydrogen atoms of the methyl group have been replaced by chlorine atoms. The salts and esters of dichloroacetic acid are called dichloroacetates. Salts of DCA have been studied as potential drugs because they inhibit the enzyme pyruvate dehydrogenase kinase.

Cancer cells change the way they metabolize oxygen in a way that promotes their survival. In laboratory studies of isolated cancer cells grown in tissue culture, DCA restores the original metabolism, and promotes their self-destruction. This has led to the use of DCA for treating cancer, by individuals experimenting with it themselves, by doctors administering it to patients as a non-approved drug, by scientists testing it in cancer tissue cultures in cell culture and in mice, and in human Phase II studies. DCA has improved certain biochemical parameters, but it has not demonstrated improved survival.

A study in mice at the University of Alberta showed that "DCA induces apoptosis, decreases proliferation, and inhibits tumor growth, without apparent toxicity."[4] In 2010, a small human trial on 5 cancer patients and 49 samples of tissue was conducted.[5] The results were encouraging and DCA "appeared to extend the lives of four of the five study participants".[6]

Immunity Gene ‘Cures’ Bay Area Man Of AIDS

Source

(AP)

SAN FRANCISCO (CBS 5) — A 45-year-old man now living in the Bay Area may be the first person ever cured of the deadly disease AIDS, the result of the discovery of an apparent HIV immunity gene.

Timothy Ray Brown tested positive for HIV back in 1995, but has now entered scientific journals as the first man in world history to have that HIV virus completely eliminated from his body in what doctors call a “functional cure.”

Brown was living in Berlin, Germany back in 2007, dealing with HIV and leukemia, when scientists there gave him a bone marrow stem cell transplant that had astounding results.

“I quit taking my HIV medication the day that I got the transplant and haven’t had to take any since,” said Brown, who has been dubbed “The Berlin Patient” by the medical community.

Brown’s amazing progress continues to be monitored by doctors at San Francisco General Hospital and at the University of California at San Francisco medical center.

“I’m cured of HIV. I had HIV but I don’t anymore,” he said, using words that many in the scientific community are cautiously clinging to.

Scientists said Brown received stem cells from a donor who was immune to HIV. In fact, about one percent of Caucasians are immune to HIV. Some researchers think the immunity gene goes back to the Great Plague: people who survived the plague passed their immunity down and their heirs have it today.

UCSF’s Dr. Jay Levy, who co-discovered the HIV virus and is one of the most respected AIDS researchers in the world, said this case opens the door to the field of “cure research,” which is now gaining more attention.

“If you’re able to take the white cells from someone and manipulate them so they’re no longer infected, or infectable, no longer infectable by HIV, and those white cells become the whole immune system of that individual, you’ve got essentially a functional cure,” he explained.

UCSF’s Dr. Paul Volberding, another pioneering AIDS expert who has studied the disease for all of its 30 years cautioned that while “the Berlin Patient is a fascinating story, it’s not one that can be generalized.”

Both doctors stressed that Brown’s radical procedure may not be applicable to many other people with HIV, because of the difficulty in doing stem cell transplants, and finding the right donor.

“You don’t want to go out and get a bone marrow transplant because transplants themselves carry a real risk of mortality,” Volberding said.

He explained that scientists also still have many unanswered questions involving the success of Brown’s treatment.

“One element of his treatment, and we don’t know which, allowed apparently the virus to be purged from his body,” he observed. “So it’s going to be an interesting, I think productive area to study.”

Volberding continued, “Knock on wood, (Brown) hasn’t had any recurrence now for several years of the virus, and that hasn’t happened before in our experience.”

As a result, at the San Francisco AIDS Foundation some are now using the word “cure” after so many avoided it for decades.

“You sort of felt like you couldn’t say ‘cure’ for a number of years. Scientists and clinicians and people with HIV alike felt that was a promise that was never going to be realized and it was dangerous to direct a lot of energy toward it,” said Dr. Judy Auerbach. “And now things have shifted.”

The California Institute of Regenerative Medicine is currently funding stem cell research in the Bay Area based on Brown’s case in the hopes of replicating his success for broader populations of people with HIV.

The institute said it plans to begin clinical trials next year.